LLY - Eli Lilly and Company
| Previous Close | 79.06 |
| Open | 79.43 |
| Bid | 79.66 x 100 |
| Ask | 79.67 x 200 |
| Day's Range | 79.17 - 79.77 |
| 52 Week Range | 73.69 - 89.09 |
| Volume | 1,350,342 |
| Avg. Volume | 4,975,877 |
| Market Cap | 83.113B |
| Beta | 0.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.25 (2.82%) |
| Ex-Dividend Date | 2018-02-14 |
| 1y Target Est | N/A |
- Market Realist•35 minutes ago
Eli Lilly’s 1Q18 Estimates: Revenue Growth Expected
Wall Street analysts expect an ~3.0% increase in Eli Lilly & Co.’s (LLY) 1Q18 revenues to $5.5 billion. Eli Lilly’s products are sold in more than 120 countries, and its international sales comprise ~45.0% of its total revenues. As a result, the company is exposed to currency risk, and foreign exchange is expected to have a positive impact on its overall revenues during 1Q18.
- Zacks•1 hour ago
Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN
Three pharma/biotech bigwigs are set to release earnings report on Apr 24. Let's sneak a peek into how the companies are placed ahead of the upcoming results.
- Market Realist•2 hours ago
Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings
Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.
- Market Realist•5 hours ago
Merck’s Relebactam Met Primary Endpoints in Phase 3 Study
Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections.
- Market Realist•6 hours ago
What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings
GlaxoSmithKline (GSK) is set to release its 1Q18 earnings on April 25, 2018. The below chart shows the company’s revenues and earnings per share (or EPS) since 1Q17 and analysts’ estimates for 1Q18. Analysts estimate the company will post EPS of 24.21 pence on revenues of 7.2 billion pounds in 1Q18.
- Motley Fool•2 days ago
Big Week Ahead for Eli Lilly: Here's What to Look For
Eli Lilly and Company is about to report first-quarter results after an important meeting with the FDA.
- Zacks•3 days ago
Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
- Zacks•3 days ago
Top Ranked Growth Stocks to Buy for April 20th
Top Ranked Growth Stocks to Buy for April 20th
- Motley Fool•3 days ago
Better Buy: GlaxoSmithKline plc (GSK) vs. Eli Lilly (LLY)
Which stock wins in a head-to-head matchup of these two big pharma companies?
- Motley Fool•3 days ago
3 Biotech Stocks With Major Catalysts Incoming
Highly anticipated events expected in the weeks ahead could set these three biotechs up for long-term success.
Markit•3 days agoSee what the IHS Markit Score report has to say about Eli Lilly And Co.
Eli Lilly And Co NYSE:LLY
- Bloomberg•4 days ago
Eli Lilly's Blockbuster Resurrection Story Has Holes
Its arthritis drug's new lease on FDA life apparently comes with conditions.
Yahoo Finance Video•3 hours agoEARNINGS Alphabet preview: Wall Street watching Google's costs like a hawk
Yahoo Finance's Jared Blikre and Alexis Christoforous break down the latest market action.
Yahoo Finance Video•3 days agoEARNINGS: Wall Street set the bar high, and beats are coming in stronger than the prior quarter
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
